Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02576496
Title Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mundipharma-EDO GmbH
Indications

Hodgkin's lymphoma

Waldenstroem's macroglobulinemia

hematologic cancer

multiple myeloma

prolymphocytic leukemia

peripheral T-cell lymphoma

non-Hodgkin lymphoma

Therapies

Tinostamustine

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.